Eledon Pharmaceuticals Submits IND To FDA For Registrational Tegoprubart Study In Islet Cell Transplantation For Type 1 Diabetes; Reaffirms Q4 2026 Initiation Of Phase 3 LEGACY Kidney Transplant Trial

Loading news article.

Eledon Pharmaceuticals Submits IND To FDA For Registrational Tegoprubart Study In Islet Cell Transplantation For Type 1 Diabetes; Reaffirms Q4 2026 Initiation Of Phase 3 LEGACY Kidney Transplant Trial | WAPE

Eledon Pharmaceuticals Submits IND To FDA For Registrational Tegoprubart Study In Islet Cell Transplantation For Type 1 Diabetes; Reaffirms Q4 2026 Initiation Of Phase 3 LEGACY Kidney Transplant Trial

Article summary

Related companies

Comments —